Venous thromboembolism (VTE) is the formation of blood clots inside the blood vessel. These clots restrict blood flow through the circulatory system. It is classified into two type’s deep vein thrombosis and pulmonary embolism. Formation of blood clot in a deep vein (generally in the leg) is called deep vein thrombosis. The formed deep vein thrombosis clot break off and travels to the lungs, called as pulmonary embolism. Pulmonary embolism is a serious complication from deep vein thrombosis. It occurs in almost one-third of patients suffering from deep vein thrombosis. Venous thromboembolism can occur at any age; however, it is common in adults aged 60 and above. People who are overweight, older, whose blood is thicker than normal or suffer from some other diseases such as autoimmune disorders (rheumatoid arthritis, lupus, etc.) or cancer are at a higher risk of venous thromboembolism. Hospitalization due to major trauma (fractures or immobilization) or surgery increases the risk for venous thromboembolism. Up to 60% of venous thromboembolism cases occur during or after hospitalization. Venous thromboembolism equally affects men and women. Globally, venous thromboembolism is the third most common cardiovascular disease and leading cause of death and disability.
Venous thromboembolism is a life-threatening medical condition that requires immediate medical treatment. Treatment primarily focuses on breaking the clots and preventing further formation of clots. Treatment includes blood thinning agents such as anticoagulants (such as unfractionated and low molecular weight heparin as well as warfarin), mechanical devices (compression stockings), and thrombolytic therapy (tissue plasminogen activator). The venous thromboembolism market is expected to expand in the near future, led by the development of novel oral anticoagulants (NOACs) to overcome the limitation of current treatment options and provide improved patient of care. NOACs are classified into direct thrombin inhibitors (argatroban, dabigatran), which inhibit factor IIa (thrombin), and factor Xa inhibitors (rivaroxaban, edoxaban, apixaban). NOACs offer major pharmacological benefits over current vitamin K antagonists (heparin or warfarin). These include rapid onset and offset of action, predictable pharmacokinetics, and less drug interactions, which eliminate the need for regular coagulation monitoring associated with conventional anticoagulant therapy. Increase in government expenditure, rise in incidence rate of venous thromboembolism, growth in patient awareness about treatment, and high unmet needs of current treatment options are fueling the venous thromboembolism market. However, complex pathophysiology of the disease, high cost of treatment, and side effects associated with it act as key restraints for the venous thromboembolism market.
The venous thromboembolism market can be segmented based on disease type, product type, and geography. In terms of disease type, the venous thromboembolism market can be segregated into deep vein thrombosis and pulmonary embolism. The pulmonary embolism segment is estimated to expand more than the deep vein thrombosis segment, as pulmonary embolism is the third most common cause for hospital related deaths. Based on product type, the venous thromboembolism market can be divided into anticoagulants, medical devices, and others. In anticoagulant segment, NOAC’s market is expected to grow because it eliminates the need for regular coagulation monitoring, overcoming the major limitation of current standard of care.
In terms of geography, the venous thromboembolism market can be classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the venous thromboembolism market, followed by Europe, due to the higher incidence and prevalence rate than that in Asia Pacific and Middle East & Africa, increase in demand for advance treatment, and rise in geriatric population in the region. Asia Pacific is an emerging market for venous thromboembolism due to the developing healthcare infrastructure and rising government expenditure in the healthcare industry. However, affordability issues, lack of proper treatment, and poor patient education are factors restraining the venous thromboembolism market in such as Middle East & Africa and Latin America.
Major players operating in the venous thromboembolism market include Bristol-Myers Squibb Company, Sanofi S.A., Pfizer, Inc., Daiichi Sankyo Co. Ltd., Johnson & Johnson, AbbVie Inc., Merck & Co., and Astellas Pharma Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.